Northwood, Middlesex

Study of Roginolisib in UM Patients (OCULE-01)

This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity […]

Study of Roginolisib in UM Patients (OCULE-01) Read More »

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD)

Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma.

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Read More »

Skip to content